Back to top

Image: Bigstock

Cardinal Health Inc.

Read MoreHide Full Article

Cardinal Health underperformed its industry in a year's time. Despite solid sales growth, profits in the Pharmaceutical segment were hurt by generic pharmaceutical pricing. Huge investments in Pharmaceutical IT platform and lackluster generics performance are likely to mar Cardinal Health’s operational efficiencies in the upcoming quarters. Intense competition and customer concentration are other bottlenecks. Recently, the company closed the divestiture of Cardinal Health China distribution. On the positive side, Cardinal Health’s Specialty business gained a number of Pharmaceutical Distribution customers in recent times. An exclusive profile of Medical and Pharmaceutical offerings provides the company with a competitive edge in the MedTech space. Cardinal Health is on track to deliver targeted annualized cost savings of $100 million in fiscal 2019 and higher than $200 million by the end of fiscal year 2020.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Cardinal Health, Inc. (CAH) - free report >>

Published in